Maximilian Bunz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maximilian Bunz has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Sujan Shresta
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, USA
2 shared publications Annie Elong Ngono
Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States of America
1 shared publication- Annie Elong Ngono
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, USA
1 shared publication Dan Hu
Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany
1 shared publication- Dawid S. Zyla
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, USA
1 shared publication Edward Vizcarra
Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States of America
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in The EMBO Journal
- p. 1-37
Tetraspanin CD81 restricts Ebola virus infection and is antagonized by glycoprotein GP and matrix protein VP40
Viruses manipulate host cell membranes to evade antiviral immunity, prevent superinfection, and optimize their replication and spread. The Ebola virus glycoprotein GP mediates viral entry but also contributes to the subversion of host antiviral immune responses. Here, we characterize the impact of Ebola virus GP on cell surface proteins and show that it reduces cell surface availability of tetraspanins CD81, CD63, and CD9. This function is conserved among several filoviral glycoproteins but not observed for glycoproteins of other viral families. Whereas CD63 and CD9 are largely dispensable for Ebola virus replication, CD81 suppresses virus-like particle entry and viral replication. This activity might be attributed to CD81-mediated suppression of NF-κB signaling, which is induced by the Ebola virus matrix protein VP40 and transcription- and replication-competent virus-like particle (trVLP) replication. Our results further indicate that both GP, which interacts directly with CD81, and VP40, which also associates with CD81, function to reduce total and surface expression levels of CD81. CD81 is shown to reduce levels of Ebola virus RNA species, and its antibody-mediated clustering can suppress Ebola virus infection. Our study provides insights into the roles of NF-κB signaling in Ebola virus replication and immunopathogenesis, and identifies tetraspanin CD81 as a potentially druggable Ebola virus-inhibitory host factor.
- 4 November 2026
- Published by Springer Nature in The EMBO Journal
- p. 1-37
Open AccessTetraspanin CD81 restricts Ebola virus infection and is antagonized by glycoprotein GP and matrix protein VP40
Viruses manipulate host cell membranes to evade antiviral immunity, prevent superinfection, and optimize their replication and spread. The Ebola virus glycoprotein GP mediates viral entry but also contributes to the subversion of host antiviral immune responses. Here, we characterize the impact of Ebola virus GP on cell surface proteins and show that it reduces cell surface availability of tetraspanins CD81, CD63, and CD9. This function is conserved among several filoviral glycoproteins but not observed for glycoproteins of other viral families. Whereas CD63 and CD9 are largely dispensable for Ebola virus replication, CD81 suppresses virus-like particle entry and viral replication. This activity might be attributed to CD81-mediated suppression of NF-κB signaling, which is induced by the Ebola virus matrix protein VP40 and transcription- and replication-competent virus-like particle (trVLP) replication. Our results further indicate that both GP, which interacts directly with CD81, and VP40, which also associates with CD81, function to reduce total and surface expression levels of CD81. CD81 is shown to reduce levels of Ebola virus RNA species, and its antibody-mediated clustering can suppress Ebola virus infection. Our study provides insights into the roles of NF-κB signaling in Ebola virus replication and immunopathogenesis, and identifies tetraspanin CD81 as a potentially druggable Ebola virus-inhibitory host factor.
- Open Access
- 26 August 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (10) , 2867-2882
A Zika virus vaccine with E protein fusion loop mutations protects via CD8+ T cells
- 26 August 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (10) , 2867-2882
Open AccessA Zika virus vaccine with E protein fusion loop mutations protects via CD8+ T cells
- Open Access
- 24 January 2019
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 15 (1) , e1007474
CD4+ T cells promote humoral immunity and viral control during Zika virus infection
Several Zika virus (ZIKV) vaccines designed to elicit protective antibody (Ab) responses are currently under rapid development, but the underlying mechanisms that control the magnitude and quality of the Ab response remain unclear. Here, we investigated the CD4+ T cell response to primary intravenous and intravaginal infection with ZIKV. Using the LysMCre+Ifnar1fl/fl (myeloid type I IFN receptor-deficient) C57BL/6 mouse models, we identified six I-Ab-restricted ZIKV epitopes that stimulated CD4+ T cells with a predominantly cytotoxic Th1 phenotype in mice primed with ZIKV. Intravenous and intravaginal infection with ZIKV effectively induced follicular helper and regulatory CD4+ T cells. Treatment of mice with a CD4+ T cell-depleting Ab reduced the plasma cell, germinal center B cell, and IgG responses to ZIKV without affecting the CD8+ T cell response. CD4+ T cells were required to protect mice from a lethal dose of ZIKV after infection intravaginally, but not intravenously. However, adoptive transfer and peptide immunization experiments showed a role for memory CD4+ T cells in ZIKV clearance in mice challenged intravenously. These results demonstrate that CD4+ T cells are required mainly for the generation of a ZIKV-specific humoral response but not for an efficient CD8+ T cell response. Thus, CD4+ T cells could be important mediators of protection against ZIKV, depending on the infection or vaccination context. Several vaccine candidates are currently under development for Zika virus (ZIKV) infection, which causes life-threatening neurologic diseases, including congenital Zika syndrome in neonates and Guillain-Barré syndrome in adults. However, the mechanisms by which the adaptive immune system contributes to protection against ZIKV have not been fully investigated. In this report, we used mouse models of systemic and genital mucosal infection with ZIKV to evaluate the role of CD4+ T cells in regulating antiviral humoral and CD8+ T cell responses and in controlling ZIKV infection. We first defined the antigen specificity and phenotype of the CD4+ T cell response to ZIKV and then demonstrated that CD4+ T cells are required for inducing humoral, but not CD8+ T cell, responses in ZIKV-primed mice. CD4+ T cells were also required for local control of ZIKV burden in mice infected intravaginally. Although CD4+ T cells are not necessary for the control of primary ZIKV infection via the intravenous route, CD4+ T cells can confer protection against lethal intravaginal ZIKV challenge. Our results support ZIKV vaccine strategies that induce a protective CD4+ T cell response to ZIKV.
- 24 January 2019
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 15 (1) , e1007474
Open AccessCD4+ T cells promote humoral immunity and viral control during Zika virus infection
Several Zika virus (ZIKV) vaccines designed to elicit protective antibody (Ab) responses are currently under rapid development, but the underlying mechanisms that control the magnitude and quality of the Ab response remain unclear. Here, we investigated the CD4+ T cell response to primary intravenous and intravaginal infection with ZIKV. Using the LysMCre+Ifnar1fl/fl (myeloid type I IFN receptor-deficient) C57BL/6 mouse models, we identified six I-Ab-restricted ZIKV epitopes that stimulated CD4+ T cells with a predominantly cytotoxic Th1 phenotype in mice primed with ZIKV. Intravenous and intravaginal infection with ZIKV effectively induced follicular helper and regulatory CD4+ T cells. Treatment of mice with a CD4+ T cell-depleting Ab reduced the plasma cell, germinal center B cell, and IgG responses to ZIKV without affecting the CD8+ T cell response. CD4+ T cells were required to protect mice from a lethal dose of ZIKV after infection intravaginally, but not intravenously. However, adoptive transfer and peptide immunization experiments showed a role for memory CD4+ T cells in ZIKV clearance in mice challenged intravenously. These results demonstrate that CD4+ T cells are required mainly for the generation of a ZIKV-specific humoral response but not for an efficient CD8+ T cell response. Thus, CD4+ T cells could be important mediators of protection against ZIKV, depending on the infection or vaccination context. Several vaccine candidates are currently under development for Zika virus (ZIKV) infection, which causes life-threatening neurologic diseases, including congenital Zika syndrome in neonates and Guillain-Barré syndrome in adults. However, the mechanisms by which the adaptive immune system contributes to protection against ZIKV have not been fully investigated. In this report, we used mouse models of systemic and genital mucosal infection with ZIKV to evaluate the role of CD4+ T cells in regulating antiviral humoral and CD8+ T cell responses and in controlling ZIKV infection. We first defined the antigen specificity and phenotype of the CD4+ T cell response to ZIKV and then demonstrated that CD4+ T cells are required for inducing humoral, but not CD8+ T cell, responses in ZIKV-primed mice. CD4+ T cells were also required for local control of ZIKV burden in mice infected intravaginally. Although CD4+ T cells are not necessary for the control of primary ZIKV infection via the intravenous route, CD4+ T cells can confer protection against lethal intravaginal ZIKV challenge. Our results support ZIKV vaccine strategies that induce a protective CD4+ T cell response to ZIKV.